ArticleNature communications2025

Intravenous liposomal irinotecan in metastatic triple-negative breast cancer after ≥ 2 prior lines of chemotherapy: a phase Ib study.

Ying Fan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.